Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells

Ann Rheum Dis. 2012 May;71(5):768-76. doi: 10.1136/annrheumdis-2011-200468. Epub 2012 Jan 18.

Abstract

Objective: Cardiovascular events remain the leading cause of death in rheumatoid arthritis (RA). To study the role of cytokines in these observations, the effects of tumour necrosis factor α (TNFα) and interleukin (IL)-17, a classical and a new key player in RA, were assessed in endothelial cell (EC) dysfunction.

Methods: Primary human EC were treated with IL-17 alone or combined with TNFα. mRNA expression was quantified by qRT PCR and Affymetrix microarrays. The role of IL-17 was studied using functional assays of platelet aggregation, EC migration and invasion.

Results: IL-17 alone induced 248 pro-inflammatory genes and 9803, when combined with TNFα. IL-17 plus TNFα induced synergistically chemokine genes such as CCL5, IL-8 and cytokine genes such as IL-6. In contrast, IL-17 decreased genes involved in the regulation of inflammation such as IL-33. IL-17 induced EC migration and invasion in synergy with TNFα. Such invasion was inhibited with an antiCXCR4 antibody, indicating the contribution of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 axis. Supernatants of IL-17-treated EC induced strong platelet aggregation. IL-17 inhibited endothelial CD39/ATPDase expression, an inhibitor of platelet activation. Finally, IL-17 enhanced genes critical for coagulation such as tissue factor and decreased thrombomodulin, leading to a pro-thrombotic state.

Conclusion: These results indicate that IL-17 specifically when combined with TNFα has major pro-coagulant and pro-thrombotic effects on vessels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Blocking / pharmacology
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Chemokines / genetics*
  • Chemokines / metabolism
  • Drug Therapy, Combination
  • Gene Expression Regulation / drug effects*
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Human Umbilical Vein Endothelial Cells / pathology
  • Interleukin-17 / pharmacology*
  • Interleukin-33
  • Interleukins / genetics*
  • Interleukins / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Phenotype
  • Receptors, CXCR4 / immunology
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antibodies, Blocking
  • CXCR4 protein, human
  • Chemokines
  • IL33 protein, human
  • Interleukin-17
  • Interleukin-33
  • Interleukins
  • Receptors, CXCR4
  • Tumor Necrosis Factor-alpha